drugset / Trial / NCT03534037
Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction
RandomizedParallel-groupOpen-labelTreatment
Summary
Hyperuricemia is an additional risk factor for cardiovascular disease, associating with left ventricular diastolic dysfunction in individuals with metabolic syndrome. The effect of urate-lowering therapies on left ventricular diastolic dysfunction remains unclear. The study is conducted to investigate whether febuxostat or benzbromarone might improve left ventricular diastolic dysfunction in individuals with metabolic syndrome and hyperuricemia
Timeline
- Start
- 2020-02-01
- Primary completion
- 2021-12
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Benzbromarone | Small molecule | 50 mg | Oral |
| Subject | Febuxostat | Small molecule | 40 mg | Oral |